ArticleAngiogenesis2025
Micropuncture and granular hydrogel scaffolds to surgically bioengineer a perfusable and stably patterned microvasculature.
Article in Angiogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Orthogonally crosslinked gelatin methacryloyl microgels for in situ assembly of granular hydrogel scaffolds.Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Vascularization of implanted biomaterials is critical to reconstructive surgery and tissue engineering. Ultimately, the goal is to promote a rapidly perfusable hierarchical microvasculature that persists with time and can meet underlying tissue needs. We have previously shown that using a microsurgical technique, termed micropuncture (MP), in combination with porous granular hydrogel scaffolds (GHS) fabricated via interlinking hydrogel microparticles (microgels) results in a rapidly perfusable patterned microvasculature. However, whether this engineered microvasculature remains stable at longer time points remains unknown. Here, we combine MP with GHS and compare overall microvascular architecture and phenotype along with the evolving cellular landscape over a 28 day period. We demonstrate perfusable patterned microvascular stability in our MP + GHS model that occurs alongside a sustained rise in endothelial cell and macrophage recruitment. Specifically, MP yields a significant rise in M2 macrophages between the 7 and 28 day time points, suggesting ongoing microvascular remodeling, even in the presence of early pericyte stabilization. With time, the GHS microvasculature acquires a relatively equivalent arterial and venous morphology, as assessed through Ephrin-B2 and EphB4 quantification. Finally, angiography at 28 days shows that MP + GHS is associated with more perfusable microvascular loops when compared with MP + Bulk (nonporous) scaffolds. Hence, our surgically bioengineered microvasculature offers a unique opportunity to sustainably and precisely control biomaterial vascularization and ultimately advance the fields of reconstructive surgery and tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.